JP2017502092A - ヘテロアリール及びその使用 - Google Patents

ヘテロアリール及びその使用 Download PDF

Info

Publication number
JP2017502092A
JP2017502092A JP2016563905A JP2016563905A JP2017502092A JP 2017502092 A JP2017502092 A JP 2017502092A JP 2016563905 A JP2016563905 A JP 2016563905A JP 2016563905 A JP2016563905 A JP 2016563905A JP 2017502092 A JP2017502092 A JP 2017502092A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
hydrogen
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016563905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502092A5 (enExample
Inventor
インドゥ ティー． バラサン，
インドゥ ティー． バラサン，
クリス ブラックバーン，
クリス ブラックバーン，
ジェフリー ピー． シャバーリ，
ジェフリー ピー． シャバーリ，
ジョーハラ チューター，
ジョーハラ チューター，
コートニー エー． クリス，
コートニー エー． クリス，
ナタリー ダモーレ，
ナタリー ダモーレ，
ポール イー． フレミング，
ポール イー． フレミング，
ケネス エム． ギグスタッド，
ケネス エム． ギグスタッド，
クリスタ イー． ギプソン，
クリスタ イー． ギプソン，
マリオ ジラード，
マリオ ジラード，
ヨンボ フー，
ヨンボ フー，
ジャニス リー，
ジャニス リー，
ギャン リー，
ギャン リー，
マンソレ レザイ，
マンソレ レザイ，
マイケル ディー． シンチャック，
マイケル ディー． シンチャック，
フランソワ ソーシー，
フランソワ ソーシー，
スティーブン ジー． ストラウド，
スティーブン ジー． ストラウド，
トリシア ジェイ． ヴォス，
トリシア ジェイ． ヴォス，
ヒ シュー，
ヒ シュー，
インチュン イエ，
インチュン イエ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017502092A publication Critical patent/JP2017502092A/ja
Publication of JP2017502092A5 publication Critical patent/JP2017502092A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016563905A 2014-01-14 2015-01-13 ヘテロアリール及びその使用 Pending JP2017502092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927064P 2014-01-14 2014-01-14
US61/927,064 2014-01-14
US201462054757P 2014-09-24 2014-09-24
US62/054,757 2014-09-24
PCT/US2015/011250 WO2015108881A1 (en) 2014-01-14 2015-01-13 Heteroaryls and uses thereof

Publications (2)

Publication Number Publication Date
JP2017502092A true JP2017502092A (ja) 2017-01-19
JP2017502092A5 JP2017502092A5 (enExample) 2018-02-08

Family

ID=53543368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563905A Pending JP2017502092A (ja) 2014-01-14 2015-01-13 ヘテロアリール及びその使用

Country Status (4)

Country Link
US (1) US10202373B2 (enExample)
EP (1) EP3094326A4 (enExample)
JP (1) JP2017502092A (enExample)
WO (1) WO2015108881A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538918A (ja) * 2022-11-10 2025-12-03 ≪ターゲット メディカルズ≫ リミテッド ライアビリティ カンパニー ヒトアルドステロン合成酵素（ｃｙｐ１１ｂ２）の阻害剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
PL3416945T3 (pl) 2016-02-19 2020-12-28 Sprint Bioscience Ab Związki 6-arylo-4-(morfolin-4-ylo)-1h-pirydyn-2-onu przydatne w leczeniu nowotworu i cukrzycy
PT3416957T (pt) 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
HRP20220497T1 (hr) 2017-08-23 2022-05-27 Sprint Bioscience Ab Spoj morfolinilpiridona
IL302356A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridylpyridone compounds
PL3672948T3 (pl) 2017-08-23 2022-12-05 Sprint Bioscience Ab Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
IL302355A (en) * 2017-08-23 2023-06-01 Sprint Bioscience Ab Azaindolylpyridone and diazaindolylpyridone compounds
AU2020345950A1 (en) 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CA3228766A1 (en) * 2021-08-13 2023-02-16 Yasmin YU Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer
CN119894905A (zh) * 2022-09-23 2025-04-25 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562911B1 (en) 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2004289518A1 (en) 2003-11-10 2005-05-26 Merck Sharp & Dohme Limited Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
UA96964C2 (ru) 2006-12-04 2011-12-26 Астразенека Аб Соединения полициклической мочевины с антибактериальными свойствами
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
MX2010001020A (es) 2007-07-26 2010-03-01 Novartis Ag Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
JP2010539239A (ja) 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
CA2743242A1 (en) 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
WO2010135524A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
AU2010291206A1 (en) 2009-09-04 2012-02-23 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
EP2531500B1 (en) 2010-02-05 2018-01-24 Merck Patent GmbH Hetaryl-[1,8]naphthyridine derivatives
SG186871A1 (en) 2010-07-05 2013-02-28 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
ES2550939T3 (es) 2010-07-16 2015-11-13 Nivalis Therapeutics, Inc. Nuevos compuestos de dihidropiridin-2-(1H)-ona como inhibidores de la S-nitrosoglutatión reductasa y antagonistas del receptor de la neurocinina-3
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603214A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
US8478700B2 (en) 2010-08-11 2013-07-02 Brightedge Technologies, Inc. Opportunity identification and forecasting for search engine optimization
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CA2816679A1 (en) 2010-11-17 2012-05-24 Novartis Ag 3-(aminoaryl)-pyridine compounds
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
PT2655375E (pt) 2010-12-23 2015-03-02 Sanofi Sa Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101062A1 (en) 2011-01-28 2012-08-02 Novartis Ag Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
DE102011077104A1 (de) 2011-06-07 2012-12-13 Siemens Aktiengesellschaft Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom
KR101502500B1 (ko) 2011-07-01 2015-03-16 주식회사 엘지화학 비수 전해액 및 이를 이용한 리튬 이차전지
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
TW201331194A (zh) 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
AU2013222345B2 (en) 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
CA2873861C (en) 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2014083327A1 (en) 2012-11-27 2014-06-05 Md Pharma Ab Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
BR112015016580A2 (pt) 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 1, JPN6018035201, 2007, pages 65 - 73, ISSN: 0004006841 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538918A (ja) * 2022-11-10 2025-12-03 ≪ターゲット メディカルズ≫ リミテッド ライアビリティ カンパニー ヒトアルドステロン合成酵素（ｃｙｐ１１ｂ２）の阻害剤

Also Published As

Publication number Publication date
WO2015108881A1 (en) 2015-07-23
US20160333007A1 (en) 2016-11-17
US10202373B2 (en) 2019-02-12
EP3094326A1 (en) 2016-11-23
EP3094326A4 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
US10202373B2 (en) Heteroaryls and uses thereof
ES2908042T3 (es) Heteroarilos y usos de los mismos
AU2015203480B2 (en) Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor
EP2373657B1 (en) 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
DK2497772T3 (en) A compound for inhibiting mitotic progression
AU2019209470A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN105461714B (zh) 并环类pi3k抑制剂
EP3035800A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN107278202A (zh) 用于治疗炎症和癌症的杂环itk抑制剂
JP2015506347A (ja) ヘテロアリールおよびその使用
CN107921044B (zh) 用于治疗疾病的gls1抑制剂
EP2606051A1 (en) Pyrrolopyrimidine compounds and uses thereof
CN104411706B (zh) 咪唑酮类衍生物、其药物组合物和用途
AU2015209189A1 (en) Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
WO2020078362A1 (zh) 一类咪唑并芳环类化合物的制备和应用
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
TW202214634A (zh) 雜環化合物及其衍生物
HK40121672A (en) Heteroaryl heterocyclic compounds and uses thereof
HK40074266B (en) Heteroaryl heterocyclic compounds and uses thereof
HK1227295A1 (en) Heteroaryls and uses thereof
HK1163072B (en) 5, 7-dihydro-6h-pyrimido[5, 4-d][1]benzazepin-6-thiones as plk inhibitors
HK1185067A (en) Hetarylaminonaphthyridines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190329